EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma

Majdouline Bel Lakhdar iD, Ayat Mouaden iD, Mourad Zekri, Dounia Alami, Hamza Zarouf, Imad Ghfir, Hasnae Guerrouj

World Journal of Nuclear Medicine · 01.09.2024 · 23 (03) · 185-190

DOI: 10.1055/s-0044-1787731 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Nuclear Medicine, erschienen am 01.09.2024. Verfasst von Majdouline Bel Lakhdar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Academic Hospital Ibn Sina, Faculty of Medicine and Pharmacy, University Mohammed V, Souissi, Rabat, Morocco. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Differentiated thyroid carcinoma (DTC) is the most prevalent endocrine malignancy, with radioactive iodine (RAI) therapy being a standard of care. However, RAI refractoriness, occurring in a subset of patients, significantly impacts survival rates. Understanding predictive factors for RAI refractoriness is crucial for optimizing patient management.

Methods

This retrospective study analyzed data from 90 DTC patients at Ibn Sina University Hospital, Morocco. Patients were categorized into RAI-refractory (RAIR) and non-RAIR groups based on established criteria. Statistical analyses, including univariate and multivariate logistic regression, were performed to identify predictive factors of RAI refractoriness.

Results

Age at the time of diagnosis ≥ 54 years, primary tumor diameter ≥ 29 mm, and distal/nodal metastasis were independent predictors of RAIR-DTC. Additionally, the oncocytic carcinoma histological subtype significantly increased the risk of refractoriness. These findings were consistent with previous studies and underscored the importance of early detection and risk stratification.

Conclusion

Recognition of predictive factors for RAI refractoriness, including age, tumor size, distal/nodal metastasis, and histological subtype, facilitates early identification of high-risk patients. This enables timely intervention and personalized treatment strategies, particularly relevant in resource-limited settings. Further prospective studies are warranted to validate these findings and explore additional molecular markers for improved prediction of RAI refractoriness.

Schlagwörter

Stichwörter der Autor:innen

RAI refractoriness (RAIR)differentiated thyroid carcinoma (DTC)predictive factorsradioactive iodine therapy (RAI)

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Academic Hospital Ibn Sina, Faculty of Medicine and Pharmacy, University Mohammed V, Souissi, Rabat, Morocco.

ORCID-Profile: Majdouline Bel Lakhdar, Ayat Mouaden

Zitieren

APA

Bel Lakhdar, M., Mouaden, A., Zekri, M., Alami, D., Zarouf, H., Ghfir, I., & Guerrouj, H. (2024). Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma. World Journal of Nuclear Medicine, 23(03), 185-190. https://doi.org/10.1055/s-0044-1787731

Vancouver

Bel Lakhdar M, Mouaden A, Zekri M, Alami D, Zarouf H, Ghfir I, et al. Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma. World Journal of Nuclear Medicine. 2024;23(03):185-190. doi:10.1055/s-0044-1787731

BibTeX
@article{BelLakhdar2024,
  author = {Bel Lakhdar, Majdouline and Mouaden, Ayat and Zekri, Mourad and Alami, Dounia and Zarouf, Hamza and Ghfir, Imad and Guerrouj, Hasnae},
  title = {Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma},
  journal = {World Journal of Nuclear Medicine},
  year = {2024},
  volume = {23},
  number = {03},
  pages = {185--190},
  doi = {10.1055/s-0044-1787731}
}
Kostenlos starten →